CTLT: Catalent, Inc. Stock

by  •  • Comments Off on CTLT: Catalent, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 10,754.56
Enterprise Value ($M) 14,994.56
Book Value ($M) 3,542.00
Book Value / Share 19.51
Price / Book 3.04
NCAV ($M) -3,659.00
NCAV / Share -20.16
Price / NCAV -2.94

Profitability (mra)
Return on Invested Capital (ROIC) -0.05
Return on Assets (ROA) -0.04
Return on Equity (ROE) -0.11

Liquidity (mrq)
Quick Ratio 1.96
Current Ratio 2.51

Balance Sheet (mrq) ($M)
Current Assets 2,507.00
Assets 9,708.00
Liabilities 6,166.00
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 4,381.00
Operating Income -62.00
Net Income -1,043.00
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 268.00
Cash from Investing -327.00
Cash from Financing 74.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
23 hours ago 13G/A Nomura Holdings Inc 0.60 -89.80
23 hours ago 13G/A Janus Henderson Group Plc 0.10 -98.48
1 day ago 13G/A Capital World Investors 3.50 -33.70
02-14 13G/A T. Rowe Price Investment Management, Inc. 6.20 -32.39
02-13 13G/A Vanguard Group Inc 11.17 3.05
02-12 13G/A Veritas Asset Management LLP 3.58 -42.09
01-25 13G/A BlackRock Inc. 9.00 17.31

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20
2024-10-25 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended June 30, 2024 or ☐ TRANSITION REPOR
2024-09-06 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ¨ TRANSITION REPORT PURSUANT TO SECTIO
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 202
2023-12-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ______________________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 20
2023-12-08 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ¨ TRANSITION REPORT PURSUANT TO SECTIO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-13 99,809 917,547 10.88
2024-11-12 122,765 1,110,165 11.06
2024-11-11 73,446 890,325 8.25
2024-11-08 105,121 1,315,955 7.99

(click for more detail)

Similar Companies
BHC – Bausch Health Companies Inc. BHVN – Biohaven Ltd.
BMY – Bristol-Myers Squibb Company EBS – Emergent BioSolutions Inc.
ELAN – Elanco Animal Health Incorporated


Financial data and stock pages provided by
Fintel.io